STAR

Strides Pharma Science Limited

Source: NSE · Updated 4 Nov, 06:28 pm IST

Filed 29 Oct, 08:35 pm IST Q2 FY27 (Sep ’26)Consolidated₹ millions

Revenue

14,297.34

▲ 17.1% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

2,509.14

▲ 8.4% vs Q2 FY26

Net profit

1,341.18

▲ 2.0% vs Q2 FY26

EPS (₹)

14.19

▲ 2.5% vs Q2 FY26

Operating margin

17.5%

−150 bps vs Q2 FY26

Net margin

9.4%

−140 bps vs Q2 FY26

Revenue up, profit up vs Q2 FY26

Revenue+17% vs Q2 FY26 · +13% vs Q1 FY27

Profit+2% vs Q2 FY26 · −19% vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals.

Previous-quarter and year-ago figures: as originally reported in those quarters' NSE filings; filing PDF not available to confirm restatements.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	14,297.34	12,654.07	▲ 13.0%	12,208.31	▲ 17.1%
Other income	40.83	48.9	▼ 16.5%	271.4	▼ 85.0%
Total income	14,338.17	12,702.97	▲ 12.9%	12,479.71	▲ 14.9%
Total expenses	12,825.76	11,325.93	▲ 13.2%	10,850.34	▲ 18.2%
Operating profit (EBITDA)*	2,509.14	2,297.74	▲ 9.2%	2,315.67	▲ 8.4%
Profit before tax	1,495.37	2,009.01	▼ 25.6%	1,541.65	▼ 3.0%
Tax expense	163.18	341.23	▼ 52.2%	215.93	▼ 24.4%
Net profit	1,341.18	1,654.93	▼ 19.0%	1,315.24	▲ 2.0%
EPS (₹)	14.19	17.02	▼ 16.6%	13.84	▲ 2.5%
Operating margin	17.5%	18.2%	−70 bps	19.0%	−150 bps
Net margin	9.4%	13.1%	−370 bps	10.8%	−140 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ millions except EPS. Consolidated figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All Strides Pharma Science results, dividends & filings ›

Other results filed 29 Oct

ACI Archean Chemical Industries Limited›KALPATARU Kalpataru Limited›SUDARSHAN Sudarshan Pharma Industries Limited›STLNETWORK STL Networks Limited›LAURUSLABS Laurus Labs Limited›SURYODAY Suryoday Small Finance Bank Limited›ARCIL Asset Reconstruction Company (India) Limited›RBA Restaurant Brands Asia Limited›ASIANPAINT Asian Paints Limited›MONARCH Monarch Networth Capital Limited›CARERATING CARE Ratings Limited›AYMSYNTEX AYM Syntex Limited›

Today's results ›

STRIDES PHARMA SCIENCE Q2 FY27 ; NET PROFIT UP 2% AT ₹134 CR (YOY), DOWN 19% (QOQ)

REVENUE UP 17% AT ₹1,430 CR (YOY), UP 13% (QOQ)

EBITDA UP 8% AT ₹251 CR (YOY), UP 9% (QOQ)

MARGINS AT 17.5% VS 19.0% (YOY), 18.2% (QOQ)

https://resultkal.com/r/star-2026-10-29
Source: NSE filing · not investment advice

FAQ

When did Strides Pharma Science announce Q2 FY27 results?

Strides Pharma Science filed its results on NSE on 29 Oct, 08:35 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these Strides Pharma Science figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← STAR overview